From a fundamentals basis, it's hard for me to rationalize an investment in a company with a three-time loser technology.
Bluntly put, the only thing attractive about GNVC is its market cap provided you ignore the fact that it coincidentally happens to be a biotech company that has proven an inability to get even close to selling a drug.
News 
Market Data 
Discover 
